5 largest VC rounds of H1 2026
5 largest VC rounds of H1 2026 (reported by BioSpace)
News Archive
Browse all past biotechnology intelligence, clinical developments, and industry updates.
Archived Updates
Affordable Care Act insurers want more premium increases as enrollment sags
Affordable Care Act insurers want more premium increases as enrollment sags (STAT News.)
Allergan Aesthetics, Girls Inc. help map paths for women in STEM
Allergan Aesthetics, Girls Inc. help map paths for women in STEM (reported by Fierce Pharma)
Amgen recalls almost 1 million bottles of heart failure drug over quality issue
Amgen recalls almost 1 million bottles of heart failure drug over quality issue (reported by BioSpace)
Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits (reported by STAT News)
AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical
AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical (reported by BioSpace)
AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre
AstraZeneca pens $2.1B deal for challenger to Merck’s Ohtuvayre (reported by Fierce Biotech)
Bryan Johnson’s chronic disease is notoriously difficult to diagnose
Bryan Johnson’s chronic disease is notoriously difficult to diagnose (STAT News.)
CureDuchenne shines a light on birthdays for DMD patients
CureDuchenne shines a light on birthdays for DMD patients (Fierce Pharma.)
Drugmaker caught faking doctors’ petition to evade China price cut
Drugmaker caught faking doctors’ petition to evade China price cut (Fierce Pharma.)
Evonik charts $100M upgrade to Indiana drug substance plant
Evonik charts $100M upgrade to Indiana drug substance plant (reported by Fierce Pharma)
FDA halts release of new drug rejection letters
FDA halts release of new drug rejection letters (Fierce Biotech.)
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy (reported by PR Newswire)
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending (reported by BioSpace)
Lundbeck hit with untitled letter over Vyepti efficacy claims
Lundbeck hit with untitled letter over Vyepti efficacy claims (Fierce Pharma.)